Quoc-Dien Trinh1, Paul L Nguyen1, Jeffrey J Leow1, Deepansh Dalela1, Grace F Chao1, Brandon A Mahal1, Manan Nayak1, Marianne Schmid1, Toni K Choueiri1, Ayal A Aizer1. 1. Division of Urologic Surgery and Center for Surgery and Public Health (QDT, JJL, GFC, MS), Department of Radiation Oncology (PLN, BAM, MN, AAA), and Department of Medical Oncology (TKC), Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI (DD).
Abstract
BACKGROUND: Racial disparities in cancer survival outcomes have been primarily attributed to underlying biologic mechanisms and the quality of cancer care received. Because prior literature shows little difference exists in the socioeconomic status of non-Hispanic whites and Asian Americans, any difference in cancer survival is less likely to be attributable to inequalities of care. We sought to examine differences in cancer-specific survival between whites and Asian Americans. METHODS: The Surveillance, Epidemiology, and End Results Program was used to identify patients with lung (n = 130 852 [16.9%]), breast (n = 313 977 [40.4%]), prostate (n = 166 529 [21.4%]), or colorectal (n = 165 140 [21.3%]) cancer (the three leading causes of cancer-related mortality within each sex) diagnosed between 1991 and 2007. Fine and Gray's competing risks regression compared the cancer-specific mortality (CSM) of eight Asian American groups (Chinese, Filipino, Hawaiian/Pacific Islander, Japanese, Korean, other Asian, South Asian [Indian/Pakistani], and Vietnamese) to non-Hispanic white patients. All P values were two-sided. RESULTS: In competing risks regression, the receipt of definitive treatment was an independent predictor of CSM (hazard ratio [HR] = 0.37, 95% confidence interval [CI] = 0.35 to 0.40; HR = 0.55, 95% CI = 0.53 to 0.58; HR = 0.61, 95% CI = 0.60 to 0.62; and HR = 0.27, 95% CI = 0.25 to 0.29) for prostate, breast, lung, and colorectal cancers respectively, all P < .001). In adjusted analyses, most Asian subgroups (except Hawaiians and Koreans) had lower CSM relative to white patients, with hazard ratios ranging from 0.54 (95% CI = 0.38 to 0.78) to 0.88 (95% CI = 0.84 to 0.93) for Japanese patients with prostate and Chinese patients with lung cancer, respectively. CONCLUSIONS: Despite adjustment for potential confounders, including the receipt of definitive treatment and tumor characteristics, most Asian subgroups had better CSM than non-Hispanic white patients. These findings suggest that underlying genetic/biological differences, along with potential cultural variations, may impact survival in Asian American cancer patients.
BACKGROUND: Racial disparities in cancer survival outcomes have been primarily attributed to underlying biologic mechanisms and the quality of cancer care received. Because prior literature shows little difference exists in the socioeconomic status of non-Hispanic whites and Asian Americans, any difference in cancer survival is less likely to be attributable to inequalities of care. We sought to examine differences in cancer-specific survival between whites and Asian Americans. METHODS: The Surveillance, Epidemiology, and End Results Program was used to identify patients with lung (n = 130 852 [16.9%]), breast (n = 313 977 [40.4%]), prostate (n = 166 529 [21.4%]), or colorectal (n = 165 140 [21.3%]) cancer (the three leading causes of cancer-related mortality within each sex) diagnosed between 1991 and 2007. Fine and Gray's competing risks regression compared the cancer-specific mortality (CSM) of eight Asian American groups (Chinese, Filipino, Hawaiian/Pacific Islander, Japanese, Korean, other Asian, South Asian [Indian/Pakistani], and Vietnamese) to non-Hispanic white patients. All P values were two-sided. RESULTS: In competing risks regression, the receipt of definitive treatment was an independent predictor of CSM (hazard ratio [HR] = 0.37, 95% confidence interval [CI] = 0.35 to 0.40; HR = 0.55, 95% CI = 0.53 to 0.58; HR = 0.61, 95% CI = 0.60 to 0.62; and HR = 0.27, 95% CI = 0.25 to 0.29) for prostate, breast, lung, and colorectal cancers respectively, all P < .001). In adjusted analyses, most Asian subgroups (except Hawaiians and Koreans) had lower CSM relative to white patients, with hazard ratios ranging from 0.54 (95% CI = 0.38 to 0.78) to 0.88 (95% CI = 0.84 to 0.93) for Japanese patients with prostate and Chinese patients with lung cancer, respectively. CONCLUSIONS: Despite adjustment for potential confounders, including the receipt of definitive treatment and tumor characteristics, most Asian subgroups had better CSM than non-Hispanic white patients. These findings suggest that underlying genetic/biological differences, along with potential cultural variations, may impact survival in Asian American cancerpatients.
Authors: Hubert Y Pan; Gary V Walker; Stephen R Grant; Pamela K Allen; Jing Jiang; B Ashleigh Guadagnolo; Benjamin D Smith; Matthew Koshy; Chad G Rusthoven; Usama Mahmood Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-09 Impact factor: 4.254
Authors: Devon K Check; Kathleen B Albers; Kanti M Uppal; Jennifer Marie Suga; Alyce S Adams; Laurel A Habel; Charles P Quesenberry; Lori C Sakoda Journal: Lung Cancer Date: 2018-09-11 Impact factor: 5.705
Authors: Alice Yunzi L Yu; Samantha M Thomas; Gayle D DiLalla; Rachel A Greenup; E Shelley Hwang; Terry Hyslop; Carolyn S Menendez; Jennifer K Plichta; Lisa A Tolnitch; Oluwadamilola M Fayanju Journal: Cancer Date: 2021-11-18 Impact factor: 6.860
Authors: Caroline A Thompson; Scarlett Lin Gomez; Katherine G Hastings; Kristopher Kapphahn; Peter Yu; Salma Shariff-Marco; Ami S Bhatt; Heather A Wakelee; Manali I Patel; Mark R Cullen; Latha P Palaniappan Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10 Impact factor: 4.254
Authors: Lindsey A Torre; Ann M Goding Sauer; Moon S Chen; Marjorie Kagawa-Singer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2016-01-14 Impact factor: 508.702
Authors: María Elena Martínez; Kristin Anderson; James D Murphy; Susan Hurley; Alison J Canchola; Theresa H M Keegan; Iona Cheng; Christina A Clarke; Sally L Glaser; Scarlett L Gomez Journal: Cancer Date: 2016-04-11 Impact factor: 6.921